Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DFTX
SellHot AirDefinium Therapeutics, Inc. · Healthcare · United States · $5.5B · Avg Vol: $77M/d
COMPANY DESCRIPTION
Definium Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing novel small molecule therapies for rare diseases. The company's competitive potential hinges on the successful advancement of its pipeline candidates through clinical trials, aiming to address critical unmet medical needs with innovative therapeutic approaches.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | 31.4M | — |
| EPS | — | -0.53 | -0.76 | -1.54 | -2.06 | — | -3.43 | -3.16 | -1.88 | — |
| Shares | — | 132.7M | 132.7M | 75.1M | 98.8M | -25.6% | — | — | — | — |
| Debt | — | 72.0K | 14.1M | 21.9M | 40.6M | 726.0% | 36.5M | — | — | — |
| Equity | — | 150.9M | 78.1M | 241.4M | 332.3M | 30.1% | — | — | — | — |
| Op CF | — | -50.1M | -64.4M | -79.1M | -131.6M | — | -168.0M | — | — | — |
| Inv CF | -0.3M | 0 | — | 0 | -151.6M | — | — | — | — | — |
| Fin CF | — | 59.1M | 21.8M | 253.2M | 267.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DFTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc.(you) | $5.5B | 22 | Sell |
| DNTH | Dianthus Therapeutics, Inc. | $5.9B | 23 | Sell |
| ORKA | Oruka Therapeutics, Inc. | $6.0B | 27 | Sell |
| MANE | Veradermics, Incorporated | $4.1B | 22 | Sell |
| SYRE | Spyre Therapeutics, Inc. | $8.0B | 23 | Sell |
| IDYA | IDEAYA Biosciences, Inc. | $3.9B | 21 | Sell |
| SRRK | Scholar Rock Holding Corporation | $7.0B | 19 | Strong Sell |
| CGON | CG Oncology, Inc. | $6.6B | 17 | Strong Sell |
| EWTX | Edgewise Therapeutics, Inc. | $4.6B | 28 | Sell |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.9B | 30 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%